China Resources Double Crane: The holding subsidiary Xiangzhong Pharmaceutical's Sodium Valproate Oral Solution has obtained the drug registration certificate

2026-03-29 01:59:21

China Resources Double Crane announced that its holding subsidiary, Xiangzhong Pharmaceutical, has received the “Drug Registration Certificate” for sodium valproate oral solution issued by the National Medical Products Administration. This medication is suitable for generalized, partial, or other types of epilepsy, with specifications of 300ml:12g, and the drug approval number is National Medicine Standard H20263535. Xiangzhong Pharmaceutical started the research and development of this generic drug in 2021, submitted the marketing authorization application on October 22, 2024, and received approval for marketing on March 10, 2026. As of the announcement date, the company has invested a total of 4.9375 million yuan in the research and development of this drug.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.